AustraliaHealth

Proteomics International (ASX:PIQ) received a notice of acceptance from IP Australia for a patent covering its PromarkerEndo blood test.

Alterity Therapeutics (ASX:ATH) secured a new U.S. composition of matter patent for its lead drug asset, ATH434.

Pro Medicus (ASX:PME) secured a seven-year, $23 million contract with St Luke's Health System to deploy its Visage 7 platform.

Anteris Technologies (ASX:AVR) reported financial results for the quarter ended June 30, alongside operational updates for its clinical trials.

TruScreen Group (ASX:TRU) appointed new distributors across Nigeria, Ghana, Côte d'Ivoire, and Rwanda to support public cancer screening programmes.

Starpharma (ASX:SPL) completed a fully underwritten entitlement offer to raise $32 million in new capital before costs.

Nanoveu (ASX:NVU) announced that it entered into a binding agreement with One Immersive to launch glasses-free 3D mobile films across India.

Helia Group (ASX:HLI) reported a 25% drop in first-half statutory net profit after tax to $100 million from $133.7 million.

ReNerve (ASX:RNV) secured marketing approval from India’s Central Drugs Standard Control Organisation for its NervAlign Nerve Cuff.

Austco Healthcare (ASX:AHC) entered into a binding agreement to acquire 100% of Medical Communications Systems for $2.9 million.

Integral Diagnostics (ASX:IDX) expects preliminary FY26 revenue to reach between $788 million and $790 million.

Percheron Therapeutics (ASX:PER) appointed Dr Michael Baker as CEO effective Oct. 5 to guide future trials.